Skin autofluorescence measured with fluorescent spectrometry and blood lipids level in diabetic patients

2020 ◽  
Author(s):  
Yulia A. Kononova ◽  
Daria A. Fedostsova ◽  
Ekaterina A. Dvoretskaya ◽  
Garry V. Papayan ◽  
Alina Y. Babenko ◽  
...  
Keyword(s):  
Blood Lipids ◽  
Diabetic Patients ◽  
Skin Autofluorescence

scholarly journals Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular complications

Diabetes Care ◽  
2007 ◽  
Vol 31 (3) ◽  
pp. 517-521 ◽  
Author(s):  
E. G. Gerrits ◽  
H. L. Lutgers ◽  
N. Kleefstra ◽  
R. Graaff ◽  
K. H. Groenier ◽  
...  
Keyword(s):  
At Risk ◽  
Microvascular Complications ◽  
Diabetic Patients ◽  
Skin Autofluorescence ◽  
Type 2 Diabetic Patients ◽  
Patients At Risk ◽  
Type 2 Diabetic

PO23-769 ATORVASTATIN IN DIABETIC PATIENTS: CORRELATION BETWEEN OUTCOMES, BLOOD LIPIDS, AND EXERCISE GATED SPECT DATA

2007 ◽  
Vol 8 (1) ◽  
pp. 205
Author(s):  
T. Vakhtangadze ◽  
F. Todua ◽  
D. Gachechiladze ◽  
M. Akhvlediani ◽  
G. Antelava
Keyword(s):  
Gated Spect ◽  
Blood Lipids ◽  
Diabetic Patients

scholarly journals The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

PPAR Research ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-15 ◽  
Author(s):  
Jussi Sutinen
Keyword(s):  
Highly Active Antiretroviral Therapy ◽  
Blood Lipids ◽  
Current Data ◽  
Diabetic Patients ◽  
Metabolic Complications ◽  
Highly Active ◽  
The Poor ◽  
Subcutaneous Adipose ◽  
Harmful Effects

Highly active antiretroviral therapy (HAART)-associated metabolic complications include lipoatrophy (loss of subcutaneous adipose tissue (SAT)) and insulin resistance. Thiazolidinediones are insulin-sensitizing antidiabetic agents which—as an untoward side effect in obese diabetic patients—increase SAT. Furthermore, troglitazone has improved lipoatrophy and glycemic control in non-HIV patients with various forms of lipodystrophy. These data have led to 14 clinical trials to examine whether thiazolidinediones could be useful in the treatment of HAART-associated metabolic complications. The results of these studies indicate very modest, if any, effect on lipoatrophic SAT, probably due to ongoing HAART negating the beneficial effect. The benefit might be more prominent in patients not taking thymidine analoges. Despite the poor effect on lipoatrophy, thiazolidin-ediones improved insulin sensitivity. However, especially rosiglitazone induced harmful effects on blood lipids. Current data do not provide evidence for the use of thiazolidinediones in the treatment of HAART-associated lipoatrophy, but treatment of lipoatrophy-associated diabetes may be warranted. The role of thiazolidinediones for novel indications, such as hepatosteatosis, should be studied in these patients.

Long Term Effects of Oral Vitamin E Supplement in Type II Diabetic Patients

2005 ◽  
Vol 75 (5) ◽  
pp. 341-346 ◽  
Author(s):  
Boshtam ◽  
Rafiei ◽  
Golshadi ◽  
Ani ◽  
Shirani ◽  
...  
Keyword(s):  
Vitamin E ◽  
Blood Lipids ◽  
Serum Insulin ◽  
Serum Vitamin ◽  
Enzyme Linked Immunosorbent Assay ◽  
Controlled Clinical Trial ◽  
Antioxidant Vitamin ◽  
Diabetic Patients ◽  
Type Ii ◽  
Cardiovascular Research

This triple-blind, placebo-controlled clinical trial was conducted to determine the effect of the vitamin E on fasting blood sugar (FBS), serum insulin, and glycated hemoglobin (GHb) in type II diabetic patients (NIDDM). A total of 100 patients, with no complications, aged 20–60 years old were chosen from those consulting the Isfahan Social Security Service Diabetes Clinic and divided randomly into two treated and placebo groups, and matched for age, sex, level of education, and occupation. The treated and placebo groups were given vitamin E tablets (200 IU/day) and placebo respectively. Serum vitamin E, total cholesterol (TC), triglycerides (TG), FBS, insulin, and GHb were measured at the beginning and at the end of the study (a period of 27 weeks); FBS, GHb and insulin levels were also determined several times during the period. Blood lipids and FBS were measured using the ELAN 2000 autoanalyzer at the Isfahan Cardiovascular Research Center, while for measuring insulin the enzyme-linked immunosorbent assay (ELISA) method was used; GHb was determined calorimetrically (thiobarbituric acid), and for vitamin E measurements the Hansen and Warwick method was used, by which the vitamin E was determined fluorometrically. The findings of this study show no effect of vitamin E supplementation in the patients: GHb did not change appreciably, FBS was reduced nonsignificantly (–4.3% in the treated group vs. –14.0% in the placebo group, p < 0.05). In the case of insulin, no increase was seen; instead, a decrease was observed (slightly more than 17% in the two groups, p = 0.15). No changes were observed in the levels of blood lipids. It was concluded that a daily vitamin E supplement of 200 IU for a period of 27 weeks does not affect insulin, GHb, or FBS in type II diabetic patients. However, since this antioxidant vitamin is beneficial in other ways in these patients, it would seem justified to recommend its use. Certainly, more extensive research is necessary to draw definite conclusions.

THE EFFECT OF SOY PROTEIN WITH LOW CALORIE DIET ON BLOOD LIPIDS IN HYPERLIPIDEMIC TYPE 2 DIABETIC PATIENTS

2008 ◽  
Vol 15 (3) ◽  
pp. 398-406 ◽  
Author(s):  
MOSTAFA NOROOZI ◽  
ROZA ZAVOSHY ◽  
HASSAN JAHANI HASHEMI ◽  
SAEED ASEFZADEH
Keyword(s):  
Soy Protein ◽  
Blood Lipids ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Type 2 Diabetic

scholarly journals Insights into Cardiovascular Disease Risk Based on Platelet Indices and Lipid Ratios in Reference to Glycemic Control and Duration of Diabetes

2020 ◽  
Vol 9 (2) ◽  
pp. 55-60
Author(s):  
Prabodh Risal ◽  
Rajendra Dev Bhatt ◽  
Nikita Sakhakarmi ◽  
Saroj Thapa ◽  
Surendra Koju
Keyword(s):  
Cardiovascular Disease ◽  
Glycemic Control ◽  
Blood Lipids ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Control Group ◽  
Diabetic Patients ◽  
Platelet Indices ◽  
Duration Of Diabetes ◽  
Lipid Ratios

Background: Diabetic patients are at the risk of untimely atherosclerotic cardiovascular disease. The level of blood lipids, their ratios, glycosylated hemoglobin, and platelet indices are potential markers for the assessment of cardiovascular disease risk in diabetic patients. This study aims to insights into cardiovascular disease risk among diabetic patients in reference to glycemic control and duration of diabetes on the basis of lipid ratios and platelet indices by comparing with healthy controls. Materials and Methods: A case control study was carried out among the patients, diagnosed as type 2 diabetes mellitus at Dhulikhel hospital-Kathmandu University hospital. Socio-demographic questionnaire, anthropometric measurements, and biochemical tests was performed. Descriptive analysis and independent T-test for the testing relationship between categorical variables along with correlation was done. Results: Nearly one-third of diabetic patients were under poor glycemic control with high risk of cardiovascular diseases on the basis of blood lipid ratios and platelet indices. Cardiac risk ratio, Atherogenic Index of Plasma, and Atherogenic Coefficient was found to be significantly high in diabetic compared to the control group (5.22±1.54 vs. 3.71±0.99, p <0.05), (0.33±0.18 vs. 0.22±0.14, p <0.05), (4.22±1.54 vs. 2.71±0.99, p <0.05) respectively. Similarly Mean Platelet Volume was also significantly higher in diabetic compared to the control group (10.16±1.43 vs. 9.06±0.81, p <0.05). Conclusion: Poor glycemic control seems riskier than prolonged diabetes on the basis of blood lipids, their ratios and platelet indices.

scholarly journals Skin Autofluorescence Profile in Tunisian Subjects with and Without Metabolic Disorders

2021 ◽  
Author(s):  
Ines Khochtali ◽  
Wahid Bouida ◽  
Hamdi Boubaker ◽  
Semir Nouira ◽  
Mohsen Kerkeni
Keyword(s):  
Metabolic Disorders ◽  
Cross Sectional Study ◽  
Tunisian Population ◽  
Diabetic Patients ◽  
Skin Autofluorescence ◽  
Clinical Tool ◽  
Cross Sectional ◽  
Hypertensive Patients ◽  
Healthy Group ◽  
Duration Of Diabetes

Abstract Background: The AGE Reader, as a clinical tool for non invasive assessment, measures the accumulation of advanced glycation end products (AGEs) in skin tissues shown as skin autofluorescence (SAF). AGEs Accumulation has been implicated in several diseases. There is no data about SAF profile in Tunisian population, this study aimed to assess firstly SAF profile in subjects with and without metabolic disorders and secondly to examine the association between SAF and various clinical parameters.Methods: In a cross-sectional study, we included 220 participants between 19 and 86 years of age who were subdivided in two groups: a healthy group (n=93) and patients group with metabolic disorders (n=127) contains three subgroups as following: diabetic patients (n=32), hypertensive patients (n=54) and patients with both diabetes and hypertension (n=41). Skin AGEs accumulation was measured by AGE Reader and clinical data was obtained.Results: SAF was significantly higher in patients group compared to healthy group [2.40 AU (2.10-2.60) vs. 2.00 AU (1.70-2.10) respectively; P <0.001]. Diabetic patients and hypertensive patients showed an increased level of SAF. The highest of SAF was observed in patient with both coexistence of diabetes, hypertension and dyslipidemia. SAF was associated with age, gender, BMI, duration of diabetes, HbA1c, triglyceride and obesity. Multivariate analysis showed that age and duration of diabetes were independent determinant of SAF. The ROC analysis indicated that an SAF > 2.25 AU was optimal cut-off point to predict the presence of metabolic disorders (P <0.001). Conclusion: SAF was increased in patients with diabetes and/or with hypertension and dyslipidemia. AGE Reader device is a rapid and helpful tool in clinical practice for evaluating and screening metabolic disorders in undiagnosed subjects.

Sign in / Sign up

Export Citation Format

Share Document